GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Shares Outstanding (Basic Average)

Innovent Biologics (STU:6IB) Shares Outstanding (Basic Average) : 1,584.0 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Innovent Biologics's average basic shares outstanding for the quarter that ended in Dec. 2023 was 1,584.0 Mil.


Innovent Biologics Shares Outstanding (Basic Average) Historical Data

The historical data trend for Innovent Biologics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Shares Outstanding (Basic Average) Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial 1,177.69 1,357.01 1,455.61 1,490.12 1,559.64

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,460.99 1,465.03 1,515.22 1,535.32 1,583.95

Innovent Biologics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Innovent Biologics  (STU:6IB) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Innovent Biologics Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (STU:6IB) Business Description

Industry
Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines